Recombinant activated factor seven in acute life-threatening bleeding in neonates: report on three cases and review of literature.
BACKGROUND
Acute bleeding of different genesis can be a severe, life-threatening problem in neonatology. Recombinant factor seven (rFVIIa) is known to have unique hemostatic properties in adults and older children.


METHODS
Three cases of acute life-threatening peri- and postnatal hemorrhage were successfully controlled after the application of fFVIIa. All infants were first treated with vitamin K, fresh-frozen plasma and platelet transfusion.


CONCLUSIONS
The cases substantiate other reports that rFVIIa is an effective treatment for acute, refractory and life-threatening bleeding in neonates and premature infants.
Hünseler
C
C
Department of Neonatology, Children's Hospital of the University of Cologne, Cologne, Germany. ch@kksk.de
Kribs
A
A
Eifinger
F
F
Roth
B
B
D005167:Factor VII / Q000627:therapeutic use*; D005260:Female; D006470:Hemorrhage / Q000188:drug therapy* / Q000503:physiopathology; D006487:Hemostasis / Q000187:drug effects; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000188:drug therapy*; D008297:Male; D011994:Recombinant Proteins / Q000627:therapeutic use*; D016896:Treatment Outcome
D011994:Recombinant Proteins; D005167:Factor VII